Table 2.
Subgroup meta-analyses of CYP1A2 SNPs and cancer risk according to study design, ethnicity and tumour site
| Number cases/controls | Recessive model | |||||
|---|---|---|---|---|---|---|
| Exposed | Not exposed | OR° | 95 % CI° | I 2 (%) | P value for heterogeneity | |
| rs762551 | 3373/4006 | 29,808/36,562 | 1.03 | 0.96–1.12 | 50.4 | <0.01 |
| Study design | ||||||
| Hospital based | 1048/1110 | 8289/8482 | 1.03 | 0.88–1.20 | 60.3 | <0.01 |
| Population based | 2314/2869 | 21,326/27,820 | 1.05 | 0.96–1.15 | 41.8 | <0.01 |
| Study sample size | ||||||
| Large | 2883/3387 | 27,381/32,680 | 1.02 | 0.94–1.11 | 55.9 | <0.01 |
| Small | 490/619 | 2427/3882 | 1.09 | 0.90–1.32 | 36.0 | 0.05 |
| Ethnicity | ||||||
| Asian | 348/414 | 2539/2874 | 0.95 | 0.72–1.27 | 54.6 | 0.02 |
| Caucasian | 2132/2600 | 18,305/23,388 | 1.03 | 0.94–1.13 | 42.4 | <0.01 |
| Mixed | 893/992 | 8964/10,300 | 1.05 | 0.89–1.25 | 62.8 | <0.01 |
| Tumour site | ||||||
| Bladder | 392/436 | 3038/2806 | 0.84 | 0.70–1.01 | 28.5 | 0.23 |
| Breast | 1097/1280 | 10,285/13,269 | 1.17 | 0.94–1.45 | 79.2 | <0.01 |
| Colorectum | 803/934 | 7755/9199 | 1.03 | 0.93–1.14 | 0.0 | 0.56 |
| Endometrium | 258/391 | 1095/1898 | 1.06 | 0.87–1.30 | 0.0 | 0.85 |
| Liver | 12/26 | 235/330 | 0.63 | 0.30–1.32 | 5.0 | 0.31 |
| Lung | 221/265 | 1536/2446 | 1.20 | 0.87–1.64 | 58.9 | 0.01 |
| Ovaries | 27/34 | 349/478 | 1.31 | 0.33–5.19 | 80.3 | 0.01 |
| Pancreas | 107/142 | 1296/1656 | 1.04 | 0.80–1.36 | 0.0 | 0.87 |
| Stomach | 46/141 | 425/1258 | 0.85 | 0.59–1.21 | 0.0 | 0.45 |
| UADT | 186/192 | 1670/1631 | 0.97 | 0.73–1.29 | 29.9 | 0.23 |
| Number cases/controls | Dominant model | |||||
| Exposed | Not exposed | OR | 95 % CI | I 2 (%) | P value for heterogeneity | |
| rs2069514 | 1229/1373 | 3333/5026 | 0.99 | 0.81–1.21 | 60.0 | <0.01 |
| Study design | ||||||
| Hospital based | 758/783 | 1727/2329 | 1.01 | 0.73–1.40 | 73.7 | <0.01 |
| Population based | 471/590 | 1606/2697 | 0.94 | 0.78–1.14 | 10.6 | 0.35 |
| Study sample size | ||||||
| Large | 969/1085 | 2691/3736 | 0.97 | 0.86–1.09 | 0.0 | 0.89 |
| Small | 260/288 | 642/1290 | 1.18 | 0.65–2.11 | 81.1 | <0.01 |
| Ethnicity | ||||||
| Asian | 1093/1235 | 1297/1388 | 0.96 | 0.86–1.07 | 0.0 | 0.86 |
| Caucasian | 136/138 | 2036/3638 | 1.16 | 0.63–2.14 | 75.7 | <0.01 |
| Tumour site | ||||||
| Bladder | 236/237 | 352/326 | 0.92 | 0.73–1.17 | 0.0 | 0.81 |
| Colorectum | 447/458 | 836/847 | 0.96 | 0.65–1.43 | 53.2 | 0.07 |
| Liver | 315/409 | 324/393 | 0.94 | 0.76–1.15 | 0.0 | 0.68 |
| Lung | 211/219 | 1397/1881 | 1.16 | 0.68–1.99 | 76.3 | <0.01 |
| Number cases/controls | Dominant model | |||||
| Exposed | Not exposed | OR | 95 % CI | I 2 (%) | P value for heterogeneity | |
| rs2069526 | 139/202 | 1486/2144 | 0.94 | 0.70–1.26 | 20.7 | 0.27 |
| Study design | ||||||
| Hospital based | 35/78 | 706/1236 | 0.89 | 0.47–1.72 | 53.9 | 0.09 |
| Population based | 104/124 | 780/908 | 0.94 | 0.71–1.25 | 0.0 | 0.59 |
| Study sample size | ||||||
| Large | 121/151 | 1137/1181 | 0.85 | 0.56–1.28 | 49.4 | 0.12 |
| Small | 18/51 | 349/963 | 1.29 | 0.71–2.35 | 0.0 | 0.89 |
| Ethnicity | ||||||
| Caucasian | 139/202 | 1486/2144 | 0.94 | 0.70–1.26 | 20.7 | 0.27 |
| Tumour site | ||||||
| Colorectum | 74/93 | 737/788 | 0.91 | 0.66–1.26 | 0.0 | 0.40 |
| Lung | 60/75 | 676/811 | 0.90 | 0.47–1.71 | 55.4 | 0.08 |
| Number cases/controls | Recessive model | |||||
| Exposed | Not exposed | OR | 95 % CI | I 2 (%) | P value for heterogeneity | |
| rs2470890 | 1106/1187 | 4559/5538 | 1.11 | 0.96–1.28 | 39.0 | 0.09 |
| Study design | ||||||
| Hospital based | 429/480 | 2594/3069 | 1.10 | 0.95–1.27 | 0.0 | 0.46 |
| Population based | 655/670 | 1783/2219 | 1.09 | 0.80–1.50 | 70.5 | 0.02 |
| Study sample size | ||||||
| Large | 1077/1043 | 4390/4714 | 1.11 | 0.94–1.30 | 50.9 | 0.04 |
| Small | 29/144 | 169/824 | 1.07 | 0.69–1.66 | 0.0 | 0.85 |
| Ethnicity | ||||||
| Asian | 28/42 | 873/975 | 0.77 | 0.37–1.64 | 55.4 | 0.13 |
| Caucasian | 863/957 | 2904/3525 | 1.07 | 0.96–1.20 | 0.0 | 0.47 |
| Mixed | 215/188 | 782/1038 | 1.44 | 1.16–1.80 | 0.0 | 0.41 |
| Tumour site | ||||||
| Breast | 222/189 | 866/1025 | 1.17 | 0.65–2.08 | 73.4 | 0.05 |
| Colorectum | 500/509 | 866/929 | 1.10 | 0.94–1.28 | 0.0 | 0.51 |
| Lung | 48/77 | 348/520 | 0.92 | 0.63–1.37 | 0.0 | 0.47 |
| UADT | 294/262 | 1535/1528 | 1.20 | 0.83–1.74 | 65.7 | 0.09 |
| Number cases/controls | Recessive model | |||||
| Exposed | Not exposed | OR | 95 % CI | I 2 (%) | P value for heterogeneity | |
| rs2472304 | 127/172 | 975/1107 | 0.84 | 0.64–1.09 | 0.0 | 0.43 |
| Study design | ||||||
| Population based | 85/120 | 261/395 | 0.82 | 0.51–1.30 | 40.4 | 0.20 |
| Study sample size | ||||||
| Large | 112/136 | 878/846 | 0.79 | 0.59–1.05 | 0.0 | 0.41 |
| Ethnicity | ||||||
| Caucasian | 92/121 | 346/383 | 0.72 | 0.52–0.99 | 0.0 | 0.61 |
| Tumour site | ||||||
| Breast | 42/52 | 714/712 | 0.94 | 0.61–1.45 | 0.0 | 0.43 |
| Number cases/controls | Dominant model | |||||
| Exposed | Not exposed | OR | 95 % CI | I 2 (%) | P value for heterogeneity | |
| rs35694136 | 439/419 | 839/1183 | 1.37 | 0.78–2.42 | 89.0 | <0.01 |
| Study design | ||||||
| Hospital based | 290/263 | 373/379 | 1.46 | 0.56–3.77 | 92.7 | <0.01 |
| Population based | 149/156 | 466/804 | 1.28 | 0.77–2.13 | 68.4 | 0.08 |
| Study sample size | ||||||
| Large | 290/319 | 632/970 | 1.11 | 0.75–1.64 | 69.8 | 0.04 |
| Small | 149/100 | 207/213 | 1.78 | 0.37–8.60 | 94.6 | <0.01 |
| Ethnicity | ||||||
| Caucasian | 255/241 | 635/898 | 1.04 | 0.70–1.53 | 62.0 | 0.05 |
| Mixed | 184/178 | 204/285 | 2.73 | 0.28–27.09 | 97.3 | <0.01 |
| Tumour site | ||||||
| Lung | 149/156 | 466/804 | 1.28 | 0.77–2.13 | 68.4 | 0.08 |
Statistically significant ORs are presented in bold. °OR (95 % CI) Odds Ratio and 95 % Confidence Interval